JP2015504675A5 - - Google Patents

Download PDF

Info

Publication number
JP2015504675A5
JP2015504675A5 JP2014552305A JP2014552305A JP2015504675A5 JP 2015504675 A5 JP2015504675 A5 JP 2015504675A5 JP 2014552305 A JP2014552305 A JP 2014552305A JP 2014552305 A JP2014552305 A JP 2014552305A JP 2015504675 A5 JP2015504675 A5 JP 2015504675A5
Authority
JP
Japan
Prior art keywords
fragment
subject
nucleic acid
aat
acid encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014552305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504675A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/021057 external-priority patent/WO2013106589A1/en
Publication of JP2015504675A publication Critical patent/JP2015504675A/ja
Publication of JP2015504675A5 publication Critical patent/JP2015504675A5/ja
Priority to JP2018018033A priority Critical patent/JP6920230B2/ja
Pending legal-status Critical Current

Links

JP2014552305A 2012-01-10 2013-01-10 アルファ−１アンチトリプシン融合分子の組成物、方法、及び使用 Pending JP2015504675A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018018033A JP6920230B2 (ja) 2012-01-10 2018-02-05 アルファ−１アンチトリプシン融合ポリペプチド、それをコードする核酸構築体、及びそれらの組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261585182P 2012-01-10 2012-01-10
US61/585,182 2012-01-10
US201261586038P 2012-01-12 2012-01-12
US61/586,038 2012-01-12
US201261614391P 2012-03-22 2012-03-22
US61/614,391 2012-03-22
PCT/US2013/021057 WO2013106589A1 (en) 2012-01-10 2013-01-10 Compositions, methods and uses for alpha-1 antitrypsin fusion molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018018033A Division JP6920230B2 (ja) 2012-01-10 2018-02-05 アルファ−１アンチトリプシン融合ポリペプチド、それをコードする核酸構築体、及びそれらの組成物

Publications (2)

Publication Number Publication Date
JP2015504675A JP2015504675A (ja) 2015-02-16
JP2015504675A5 true JP2015504675A5 (enExample) 2016-03-03

Family

ID=48781909

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014552305A Pending JP2015504675A (ja) 2012-01-10 2013-01-10 アルファ−１アンチトリプシン融合分子の組成物、方法、及び使用
JP2018018033A Expired - Fee Related JP6920230B2 (ja) 2012-01-10 2018-02-05 アルファ−１アンチトリプシン融合ポリペプチド、それをコードする核酸構築体、及びそれらの組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018018033A Expired - Fee Related JP6920230B2 (ja) 2012-01-10 2018-02-05 アルファ−１アンチトリプシン融合ポリペプチド、それをコードする核酸構築体、及びそれらの組成物

Country Status (7)

Country Link
US (3) US10478508B2 (enExample)
EP (1) EP2802653A4 (enExample)
JP (2) JP2015504675A (enExample)
KR (2) KR20140137347A (enExample)
AU (3) AU2013202648B2 (enExample)
CA (1) CA2896951A1 (enExample)
WO (1) WO2013106589A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2520654T3 (en) 2003-08-26 2017-05-01 Univ Colorado Regents Inhibitors of serine protease activity and their use in methods and compositions for the treatment of bacterial infections
EP3628327A1 (en) 2011-06-24 2020-04-01 The Regents of the University of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
SMT201900520T1 (it) 2011-06-28 2019-11-13 Inhibrx Lp Polipeptidi di fusione serpinici e relativi metodi d'uso
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
MX365403B (es) 2012-01-09 2019-05-31 Serpin Pharma Llc Peptidos y metodos para usarlos.
CN105431165A (zh) 2013-05-15 2016-03-23 莫尔研究应用有限公司 用于治疗心肺手术后的术后并发症的组合物和方法
US20170190762A1 (en) 2014-06-11 2017-07-06 Beth Israel Deaconess Medical Center, Inc. Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases
US10744179B2 (en) * 2014-09-18 2020-08-18 The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy Method for treatment of inflammatory skin disorders with inhibitors of IL-36 proteolytic processing
MX2017005467A (es) * 2014-10-27 2017-11-30 Inhibrx Lp Polipéptidos de fusión de serpina y métodos para utilizar los mismos.
AU2016317726B2 (en) 2015-08-28 2022-05-26 Serpin Pharma, Llc Methods for treatment of diseases
ES3059603T3 (en) 2017-12-01 2026-03-23 Csl Behring Llc A1at for treating acute graft versus host disease after hematopoeitic cell transplantation
EP3802587A4 (en) * 2018-06-07 2022-03-23 Prottech Inc. PHARMACEUTICAL COMPOSITION WITH A FUSION PROTEIN AND THEIR USE
WO2020026227A1 (en) * 2018-07-29 2020-02-06 Kamada Ltd- Methods and uses of alpha 1-antitrypsin for preservation of explanted organs
WO2020092448A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
EP4789728A2 (en) 2020-07-06 2026-08-12 Serpin Pharma, LLC Peptides and methods of using the same
GB202102258D0 (en) * 2021-02-17 2021-03-31 Arecor Ltd Novel composition
KR20250076724A (ko) * 2023-11-22 2025-05-30 아주대학교산학협력단 지속형 재조합 알파-1 항트립신 및 이의 용도
WO2025083294A2 (en) * 2024-02-29 2025-04-24 Ageronix SA Aat-fc fusion protein

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
GB1472700A (en) 1974-11-01 1977-05-04 Ono Pharmaceutical Co Guanidinobehzoic acid derivatives and process for preparing the same
JPS5470241A (en) 1977-11-09 1979-06-05 Ono Pharmaceut Co Ltd Guanidinobenzoic acid derivative and its preparation
GB2044760B (en) 1979-03-01 1983-03-23 Ono Pharmaceutical Co Guanidinobenzoic acid derivatives
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
JP2599585B2 (ja) 1984-06-19 1997-04-09 トランスジ−ン ソシエテ アノニム ヒトα▲下１▼−アンチトリプシン誘導体及びその製造法
US4629567A (en) 1986-03-07 1986-12-16 Smithkline-Rit Alpha-1-antiprotease purification
US5157019A (en) 1986-03-18 1992-10-20 Monsanto Company Serine protease inhibitors
US4829052A (en) 1986-06-11 1989-05-09 Monsanto Company Serine protease inhibitors
US5093316A (en) 1986-12-24 1992-03-03 John Lezdey Treatment of inflammation
US5008242A (en) 1986-12-24 1991-04-16 John Lezdey Treatment of inflammation using 1-antichymotrypsin
US4829054A (en) 1987-04-13 1989-05-09 Miles Laboratories, Inc. Method of decreasing lung damage in a host following the onset of gram negative septicemia/endotoxemia
US4857538A (en) 1987-11-30 1989-08-15 The Research Foundation Of State University Of New York New compounds for the study and treatment of microfilament organization in cells
US4963654A (en) 1989-02-13 1990-10-16 Taisho Pharmaceutical Co., Ltd. Peptide serine protease inhibitor
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5612194A (en) 1989-06-23 1997-03-18 Trustees Of The University Of Pennsylvania Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
JP2568281B2 (ja) 1989-11-17 1996-12-25 原田工業株式会社 自動車用三波共用アンテナ
US5714140A (en) 1989-12-13 1998-02-03 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting the production of bioactive IL-1 by administering M-CSF
ATE146970T1 (de) 1990-10-16 1997-01-15 John Lezdey Behandlung von entzündungen
US5134119A (en) 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
US5470970A (en) 1991-02-28 1995-11-28 Dana-Farber Cancer Institute, Inc. Maspin, a serpin with tumor suppresing activity
EP0616614A1 (en) 1991-04-18 1994-09-28 The Uab Research Foundation Compositions and methods for inhibiting elastase
US5175253A (en) 1991-04-24 1992-12-29 Washington University Binding peptides
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5216022A (en) 1991-12-19 1993-06-01 Cortech, Inc. Aromatic esters of phenylenedialkanoates as inhibitors of human neutrophil elastase
AU3968193A (en) 1992-03-26 1993-10-21 Gensia, Inc. In vivo peptide therapy
GB9209032D0 (en) 1992-04-25 1992-06-10 Ciba Geigy Ag New peptide derivatives
US5734014A (en) 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
US5604201A (en) 1993-01-08 1997-02-18 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Methods and reagents for inhibiting furin endoprotease
US5346886A (en) 1993-11-15 1994-09-13 John Lezdey Topical α-1-antitrypsin, non-aqueous lipid miscible, benzalkonium chloride compositions for treating skin
JPH0827371A (ja) 1994-05-09 1996-01-30 Japan Carlit Co Ltd:The 紫外線及び赤外線吸収樹脂組成物
EP0764151A2 (en) 1994-06-10 1997-03-26 Universitaire Instelling Antwerpen Purification of serine protease and synthetic inhibitors thereof
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
US5514653A (en) 1994-09-09 1996-05-07 Washington University Method of blocking the SEC receptor
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
US5712117A (en) 1995-02-08 1998-01-27 Zymogenetics, Inc. Cytoplasmic antiproteinase-2 and coding sequences
EP0910564B1 (en) 1995-11-28 2007-10-31 Cephalon, Inc. D-amino acid derived inhibitors of cysteine and serine proteases
WO1997024339A1 (en) 1995-12-27 1997-07-10 Ono Pharmaceutical Co., Ltd. Tetrazole derivatives and drugs containing the same as the active ingredient
WO1997033996A2 (en) 1996-03-11 1997-09-18 Bayer Corporation Human bikunin
US6072041A (en) 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery
US5780440A (en) 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
US5616693A (en) 1996-07-01 1997-04-01 Alpha Therapeutic Corporation Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
ES2293661T3 (es) 1996-11-27 2008-03-16 Genentech, Inc. Purificacion por afinidad de polipeptido en una matriz de proteinas a.
TR199901681T2 (xx) 1996-12-06 2000-03-21 Cortech, Inc. Serin proteas inhibit�rleri.
US6150332A (en) 1997-01-09 2000-11-21 Virginia Commonwealth University Method and composition for lowering low density lipoprotein cholesterol
US6124257A (en) 1997-08-28 2000-09-26 Lezdey; John Method of treatment
WO2002053092A2 (en) 2001-01-04 2002-07-11 Vascular Biogenics Ltd. Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis
US6197294B1 (en) * 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
WO2000044390A1 (en) 1999-02-01 2000-08-03 John Lezdey Treatment of bladder and gastrointestinal mastocytosis
GB9904421D0 (en) 1999-02-25 1999-04-21 Univ Edinburgh Telecommunications receiver
JP2002537810A (ja) 1999-03-01 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトセルピンタンパク質
US6849605B1 (en) 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
AU3731400A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
AU3864000A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
WO2000052034A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
US6174859B1 (en) 1999-04-06 2001-01-16 J & D Sciences, Inc. Method of treatment
ATE407697T1 (de) 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
JP2003515325A (ja) 1999-12-01 2003-05-07 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４ジスルフィドコアドメイン含有（ｆｄｃｄ）ポリヌクレオチド、ポリペプチド、および抗体
US6955845B1 (en) 2000-06-30 2005-10-18 Owens Corning Fiberglas Technology, Inc. Acoustical and thermal insulator
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7247704B2 (en) 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
EE200300408A (et) 2001-02-23 2003-12-15 Immunex Corporation Aktiivsete valkude saagise suurendamine
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
WO2002094864A2 (en) 2001-05-25 2002-11-28 Genset S.A. Human cdnas and proteins and uses thereof
AU2002317940B9 (en) 2001-06-22 2008-06-05 The Secretary Of State For Health Mycobacterial antigens expressed under low oxygen tension
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US6924267B2 (en) 2001-09-18 2005-08-02 Suomen Punainen Risti Veripalvelu Methods and active substances for protecting organs
US6797493B2 (en) 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
JP4363986B2 (ja) 2001-12-21 2009-11-11 イミュネックス・コーポレーション タンパク質の精製方法
CA2475388A1 (en) 2002-02-14 2003-08-21 William J. Rutter Chimeric molecules for cleavage in a treated host
PT1551834E (pt) 2002-05-23 2010-09-30 Novartis Vaccines & Diagnostic Compostos de quinazolinona substituídos
WO2004010989A1 (en) 2002-07-25 2004-02-05 Advances Life Sciences, Inc. Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction damage and injury in mammals
US20040220242A1 (en) 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
DK2520654T3 (en) 2003-08-26 2017-05-01 Univ Colorado Regents Inhibitors of serine protease activity and their use in methods and compositions for the treatment of bacterial infections
US20070238655A1 (en) 2003-11-12 2007-10-11 The Trustees Of The University Of Pennsylvania Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
CN1980694B (zh) 2004-05-12 2012-09-26 布赖汉姆妇女医院有限公司 凝溶胶蛋白治疗感染的用途
US8715649B2 (en) * 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
WO2009005877A2 (en) 2007-04-20 2009-01-08 Regents Of The University Of Colorado Alpha-i antitrypsin having no significant serine protease inhibitor activity
US20090227518A1 (en) 2005-12-02 2009-09-10 The Regents Of The University Of Colorado Compositions and methods for treating actin-mediated medical conditions
ES2651268T3 (es) * 2006-09-12 2018-01-25 Beth Israel Deaconess Medical Center, Inc. Composiciones que contienen alfa-1-antitripsina y métodos para su uso
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
WO2008138017A2 (en) 2007-05-08 2008-11-13 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
US20110077383A1 (en) 2007-07-03 2011-03-31 Medimmune, Llc Hinge domain engineering
WO2009015345A1 (en) * 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
CN102439044B (zh) 2009-04-22 2014-08-13 阿特根公司 通过体内持续释放维持的体内半衰期增加的融合蛋白质或融合肽以及使用所述融合蛋白质或融合肽增加体内半衰期的方法
WO2011102845A1 (en) * 2010-02-18 2011-08-25 Transtech Pharma, Inc. Rage fusion protein compositions and methods of use
US9522179B2 (en) * 2010-03-04 2016-12-20 Virginia Commonwealth University Compositions and methods for modulating cardiac conditions
WO2011156820A2 (en) * 2010-06-11 2011-12-15 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for treatment of type 1 diabetes
EP3628327A1 (en) * 2011-06-24 2020-04-01 The Regents of the University of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
SMT201900520T1 (it) 2011-06-28 2019-11-13 Inhibrx Lp Polipeptidi di fusione serpinici e relativi metodi d'uso
RU2639526C2 (ru) * 2011-06-28 2017-12-21 ИНХИБРКС ЭлЭлСи Слитые полипептиды, содержащие домен wap, и способы их применения
KR101509020B1 (ko) * 2013-05-22 2015-04-14 (주)입디 알파 1 안티트립신 융합 분자에 대한 조성물, 방법 및 용도

Similar Documents

Publication Publication Date Title
JP2014519852A5 (enExample)
JP2020171316A (ja) アルファ−１抗トリプシン融合分子のための組成物、方法および使用
JP6920230B2 (ja) アルファ−１アンチトリプシン融合ポリペプチド、それをコードする核酸構築体、及びそれらの組成物
TWI648401B (zh) 生長分化因子１５（ｇｄｆ－１５）構築體
CN106687128B (zh) 用于治疗代谢病症的组合物和方法
CN106573966B (zh) 用于治疗代谢异常的组合物和方法
JP6938565B2 (ja) Ｕｔｉ融合タンパク質
JP2015503349A5 (enExample)
IL134602A (en) Conjugates that contain the homeodomain of antennapedia
JP2015500811A5 (enExample)
CN106632682A (zh) 融合蛋白ifn-elp及其应用
IL276158B1 (en) Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
JP2015524413A5 (enExample)
WO2021228052A1 (zh) 生物大分子靶向特异性补体抑制剂及其制备方法与应用
CN101463089B (zh) 人血清白蛋白-干扰素融合蛋白及其编码基因与应用
WO2012037771A1 (zh) 蝎毒肽及其制备方法与用途
JP2009507474A5 (enExample)
JP2008502323A5 (enExample)
WO2017008638A1 (zh) 一种嵌合诺如病毒p颗粒及其制备和应用
JP2008531463A5 (enExample)
CN105693864A (zh) 一种三聚体trail蛋白及其应用
CN106552259A (zh) 一种融合蛋白及其治疗疾病的用途
JP4275065B2 (ja) キメラ拮抗物質ａｎｔｈ１
JP2024520421A5 (enExample)
CN105418767A (zh) 一种用于制备Aβ表位疫苗的融合蛋白及其制备方法和用途